All In MedTech

Device Trial Radar · NCT07929870

Effectiveness and Safety of Cellbooster Glow in Healthy Subjects

A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Glow (Stabilized Hyaluronic Acid-based Complex) on Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
SuisselleNot on our public-company list
Sponsor type
Industry
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The current post-market clinical investigation is designed to evaluate the efficacy and safety of Cellbooster Glow (CBG). For this purpose, healthy participants with signs of skin aging in the face will receive a 3-session treatment and will be followed-up over 70 days after the initial injection session. Several objective measurements of skin quality will be performed with different instruments allowing to assess skin wrinkles, elasticity, dryness, pigmentation, roughness, overall inflammation and microcirculation. Subjective clinical improvement will be evaluated, as well as participant and investigator satisfactions. The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).

Conditions

  • Wrinkle Appearance
  • Skin Hydration in Healthy Volunteers
  • Skin Pigmentation
  • Skin Laxity
  • Dark Eye Circles (Periorbital Hyperpigmentation)

Interventions

  • InjectableDevice

    An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42.Time frame: Day -7 to Day 0 and Day 42.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eurofins Dermscan Pharmascan

    Aix-en-Provence, France

  • Eurofins Dermscan Pharmascan

    Villeurbanne, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.